Table 1.
Baseline characteristics of oral cavity squamous cell carcinoma and oropharyngeal squamous cell carcinoma patient cohorts from the University Medical Center Utrecht and University Medical Center Groningen
| UMCU | UMCG | OCSCC | OPSCC | p (OCSCC vs. OPSCC) | |
|---|---|---|---|---|---|
| Total no. of cases (n = 951) | 452 (100) | 499 (100) | 512 (100) | 439 (100) | |
| Age | |||||
| Median (range) | 60 (26–88) | 60 (24–94) | 62 (24–94) | 58 (35–89) | 0.001 |
| Gender | |||||
| Male | 295 (65) | 312 (63) | 305 (60) | 302 (69) | 0.003 |
| Female | 157 (35) | 187 (37) | 207 (40) | 137 (31) | |
| Clinical T-classification | |||||
| cT1-cT2 | 213 (47) | 261 (52) | 310 (61) | 164 (37) | <0.001 |
| cT3-cT4 | 238 (52.5) | 227 (46) | 191 (37) | 274 (62) | |
| Missing | 1 (0.5) | 11 (2) | 11 (2) | 1 (1) | |
| Clinical N-classification | |||||
| cN0 | 209 (46) | 221 (44) | 334 (65) | 96 (22) | <0.001 |
| cN1-3 | 177 (39) | 278 (56) | 178 (35) | 277 (63) | |
| Missing | 66 (15) | 0 (0) | 0 (0) | 66 (15) | |
| Clinical M-classification | |||||
| cM0 | 407 (90) | 353 (71) | 401 (78) | 359 (82) | <0.001 |
| cM1 | 11 (2.5) | 4 (1) | 0 (0) | 15 (3) | |
| Missing | 34 (7.5) | 142 (28) | 111 (22) | 65 (15) | |
| Site | |||||
| Oral cavity | 212 (47) | 300 (60) | – | – | – |
| Oropharynx | 240 (53) | 199 (40) | – | – | – |
| HPV status | |||||
| Positive | 45 (10) | 53 (11) | 9 (2) | 89 (20) | <0.001 |
| Negative | 398 (88) | 414 (83) | 475 (93) | 337 (77) | |
| Missing | 9 (2) | 32 (6) | 28 (5) | 13 (3) | |
| Pathological T-classification | |||||
| pT1-pT2 | 128 (28) | 208 (42) | 294 (57) | 42 (10) | 0.036 |
| pT3-pT4 | 112 (25) | 156 (31) | 218 (43) | 50 (11) | |
| Missing | 212 (47) | 135 (27) | 0 (0) | 347 (79) | |
| Pathological N-classification | |||||
| pN0 | 104 (23) | 158 (31.5) | 233 (45.5) | 29 (6.5) | 0.001 |
| pN1-3 | 129 (28.5) | 198 (39.5) | 266 (52) | 61 (14) | |
| Missing | 219 (48.5) | 143 (29) | 13 (2.5) | 349 (79.5) | |
| Pathological stage | |||||
| I-II | 93 (21) | 115 (23) | 158 (31) | 50 (11) | <0.001 |
| III-IV | 346 (76) | 384 (77) | 354 (69) | 376 (86) | |
| Missing | 13 (3) | 0 (0) | 0 (0) | 13 (3) | |
| Primary treatment | |||||
| Surgery | 273 (60) | 371 (74) | 512 (100) | 132 (30) | <0.001 |
| (Chemo)radiotherapy | 153 (34) | 103 (20.5) | 0 (0) | 256 (58.5) | |
| Palliative | 26 (6) | 23 (5) | 0 (0) | 49 (11) | |
| Missing | 0 (0) | 2 (0.5) | 0 (0) | 2 (0.5) | |
| Neck dissection | |||||
| Yes | 233 (51) | 365 (73) | 499 (97) | 99 (22.5) | <0.001 |
| No | 193 (43) | 109 (22) | 13 (3) | 289 (66) | |
| Palliative | 26 (6) | 23 (4.5) | 0 (0) | 49 (11) | |
| Missing | 0 (0) | 2 (0.5) | 0 (0) | 2 (0.5) | |
| Postoperative (chemo)radiotherapy | |||||
| Yes | 104 (23) | 268 (54) | 283 (55) | 89 (20) | 0.012 |
| No | 169 (37) | 103 (20.5) | 229 (45) | 43 (10) | |
| Surgery not primary treatment | 153 (34) | 103 (20.5) | 0 (0) | 256 (58.5) | |
| Palliative | 26 (6) | 23 (4.5) | 0 (0) | 49 (11) | |
| Missing | 0 (0) | 2 (0.5) | 0 (0) | 2 (0.5) | |
| Extra nodal growth | |||||
| Yes | 66 (14.5) | 38 (7.5) | 93 (18) | 11 (2.5) | 0.305 |
| No | 61 (13.5) | 55 (11) | 109 (21) | 7 (1.5) | |
| Not applicable | 104 (23) | 158 (31.5) | 233 (46) | 29 (7) | |
| Missing | 221 (49) | 248 (50) | 77 (15) | 392 (89) | |
| Lymphovascular invasion | |||||
| Yes | 52 (11.5) | 44 (9) | 69 (14) | 27 (6) | 0.023 |
| No | 206 (45.5) | 288 (58) | 405 (79) | 89 (20) | |
| Missing | 194 (43) | 167 (33) | 38 (7) | 323 (74) | |
| Perineural growth | |||||
| Yes | 97 (21.5) | 90 (18) | 156 (30) | 31 (7) | 0.171 |
| No | 154 (34) | 262 (53) | 327 (64) | 89 (20) | |
| Missing | 201 (44.5) | 147 (29) | 29 (6) | 319 (73) | |
| Bone invasion | |||||
| Yes | 64 (14) | 60 (12) | 119 (23) | 5 (1) | 0.001 |
| No | 176 (39) | 20 (4) | 191 (37) | 30 (7) | |
| Missing | 212 (47) | 419 (84) | 202 (40) | 404 (92) | |
| Growth pattern | |||||
| Cohesive | 55 (12) | 5 (1) | 49 (10) | 11 (2.5) | 0.102 |
| Non-cohesive/invasive | 200 (44) | 105 (21) | 272 (53) | 33 (7.5) | |
| Missing | 197 (44) | 389 (78) | 191 (37) | 395 (90) | |
| Infiltration depth | |||||
| 0–4 mm | 21 (5) | 32 (7) | 50 (10) | 3 (0.5) | 0.211 |
| >4 mm | 219 (48) | 161 (32) | 337 (66) | 43 (10) | |
| Missing | 212 (47) | 306 (61) | 125 (24) | 393 (89.5) | |
| Differentiation grade | |||||
| Well/moderate | 189 (42) | 260 (52) | 416 (81) | 33 (7.5) | 0.007 |
| Poor/undifferentiated | 50 (11) | 51 (10) | 85 (17) | 16 (3.5) | |
| Missing | 213 (47) | 188 (38) | 11 (2) | 390 (89) | |
| Overall survival time (months) | |||||
| Median (range) | 43.5 (0–185) | 33 (0–167) | 43 (0–185) | 27 (0–168) | <0.001 |
| Overall survival status | |||||
| Alive | 185 (41) | 296 (59) | 278 (54) | 202 (46) | 0.026 |
| Dead | 241 (53) | 175 (35) | 230 (45) | 186 (42.5) | |
| Palliative | 26 (6) | 23 (5) | 0 (0) | 49 (11) | |
| Missing | 0 (0) | 5 (1) | 4 (1) | 2 (0.5) | |
The cohorts comprised oral cavity and oropharyngeal squamous cell carcinoma patients, who were treated in these hospitals between the year 1996 and 2011. Clinicopathological characteristics of all patients were retrieved from electronic medical records and formalin fixed paraffin-embedded tissues of all tumors were collected. The human papillomavirus type (HPV) status was determined using P16 immunohistochemistry and a PCR-based HPV-genotyping method
HPV human papillomavirus, OCSCC oral cavity squamous cell carcinoma, OPSCC oropharyngeal squamous cell carcinoma, UMCG University Medical Center Groningen, UMCU University Medical Center Utrecht